Lifecore Biomedical Inc (NASDAQ:LFCR) does about 213.56K shares in volume on a normal day but saw 2288930 shares change hands in the recent trading day. The company now has a market cap of 146.32M USD. Its current market price is $4.74, marking a decrease of -25.24% compared to the previous close of $6.34. The 52 week high reached by this stock is $9.09 whilst the lowest price level in 52 weeks is $4.47.
Lifecore Biomedical Inc (LFCR) has a 20-day trading average at $5.60 and the current price is -47.83% off the 52-week high compared with 6.04% distance from its 52-week low. The 50-day simple moving average of the closing price is $5.39 and its 200-day simple moving average is $6.36. If we look at the stock’s price movements over the week, volatility stands at 14.67%, which decreases to 9.28% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 39.29 to suggest the stock is neutral.
The consensus objective for the share price is $6.00, suggesting that the stock has a potential upside of 21.0% over the period.
#####
The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 20, 2023 when Stephens downgraded the stock to “Equal-Weight” and issued a price target of between $11 and $2.
The current price level is -16.55%, -12.13%, and -25.58% away from its SMA20, SMA50, and SMA200 respectively, with the LFCR price moving above the 50-day SMA on current market day. Lifecore Biomedical Inc (LFCR) stock is down -16.70% over the week and -25.71% over the past month. Its price is -23.42% year-to-date and -43.50% over the past year.
The stock last released its quarterly earnings report for quarter ended 5/31/2024, with the company’s earnings per share (EPS) of -0.22 below consensus estimates by -0.09. The company’s next earnings report forecasts estimating quarterly EPS at -0.35 and -0.6 for whole year. Expected sales for next quarter are $34.31M, which analysts say will come at $137.98M for the current fiscal year and next year at $153.8M. In addition, estimates put the company’s current quarterly revenue at an average of $27.72M.
To reach the target analysts have set, the stock logically needs to grow 21.0 percent from here.
Outstanding shares total 30.56M with insiders holding 5.83% of the shares and institutional holders owning 67.80% of the company’s common stock. The company has a return on investment of 6.70% and return on equity of 20.97%. The price to earnings ratio (P/E ratio) amounts to 20.44. The beta has a value of 0.97. Price to book ratio is 12.80 and price to sales ratio is 1.14.
#####
